
The results from the first patient to receive Vertex's treatment for type 1 diabetes, VX-880, a therapy derived from stem cells, have been a cause for celebration for the Boston-based biotech company, it reports in a press release.
The patient's need for daily insulin doses has drastically decreased after they were injected with Vertex's synthetic insulin-producing cell therapy in combination with an immunosuppressive therapy.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app